- Entry
- $7.68
- Now
- $7.52 -2.1%
- Target
- $20.93
- Score
- —
— ORIGINAL POST ·
A Look At ImmunityBio (IBRX) Valuation After FDA Anktiva Pathway And Saudi Approvals - Result: DCF Fair value of $20.93 (UNDERVALUED)
· r/Shortsqueeze
· Jan 22, 2026